In cells with activating EGFR somatic mutations, BIM’s pro-apoptotic effects are synergistic with the loss of survivin, whose downregulation enhances gefitinib-induced apoptotic death in TKI-sensitive NSCLC cells [117]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.